Table 3.
Therapeutic clinical trials testing Hsp70 and/or Grp78 (BiP) antigens.
| Title | Status | Intervention | ID |
|---|---|---|---|
| Study Using Vaccination with Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase | Completed | Heat Shock Protein 70 HSP70 | NCT00027144 |
| Vaccine Therapy in Treating Patients with Chronic Myelogenous Leukemia | Completed | Recombinant 70-kD heat-shock protein; Ganetespib; Sirolimus |
NCT00030303 |
| Vaccine Therapy in Treating Patients with Stage III or Stage IV Melanoma | Completed | OVA BiP peptide; gp209-2M antigen; recombinant 70-kD heat-shock protein; tyrosinase peptide | NCT00005633 |
| AG-858 in Patients Who Are Cytogenetically Positive After Treatment with Gleevec™ | Terminated | Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™ | NCT00058747 |
| Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT) | Suspended | Hsp70-peptide TKD/IL-2 activated, autologous NK cells | NCT02118415 |
| Personalized Cancer Vaccine in Egyptian Cancer Patients | Recruiting | Peptide cancer vaccine | NCT05059821 |
| Vaccine Therapy in Treating Patients with Stage III or Stage IV Melanoma | Completed | Anti-GRP78 monoclonal IgM antibody PAT-SM6 | NCT01727778 |